Asset Details
Do you wish to reserve the book?
Letter to the editor: Comment on “possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial”
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Letter to the editor: Comment on “possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial”
Do you wish to request the book?
Letter to the editor: Comment on “possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial”
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Letter to the editor: Comment on “possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial”
2024
Overview
We have read with keen interest the original article by Kettana et al., which investigates the potential cardioprotective effects of rosuvastatin in HER2-positive breast cancer patients undergoing chemotherapy. We appreciate the study’s meticulous methodology and its contribution to medicine oncology. However, we suggest a cautious interpretation of the results due to unmeasured confounding variables that could influence cardiotoxicity development and treatment efficacy. The study’s fixed dosing approach to rosuvastatin precludes the assessment of dose-dependent effects, prompting a recommendation for future dose–response analyses. We also highlight the need to incorporate patient-reported outcomes for a more holistic treatment efficacy evaluation. Furthermore, we propose metabolomic analysis to uncover the drug’s mechanisms of action and computational methods like molecular docking to predict its potential targets, which could refine drug design and inform personalized treatment strategies. Our commentary aims to refine the study’s conclusions and encourage research that maximizes the understanding and clinical management of chemotherapy-induced cardiotoxicity.
Publisher
Springer US,Springer Nature B.V
Subject
Antineoplastic Agents - adverse effects
/ Breast Neoplasms - drug therapy
/ Cardiotoxicity - prevention & control
/ Female
/ Humans
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
/ Medicine
/ Oncology
/ Randomized Controlled Trials as Topic
